Instituto Conmemorativo Gorgas de Estudios de la Salud Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2010
NCT01083576
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Instituto Conmemorativo Gorgas de Estudios de la Salud

Active Ingredients

Drugs in Phase 3 Trials (3)

meglumine antimoniate (1 trial)

miltefosine (impavido) (1 trial)

paromomycin (humatin) (2 trials)

Drugs in Phase 2 Trials (1)

gentamicin (garamycin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4